Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 64Breast Neoplasms 63Lymphoma 58Ovarian Neoplasms 51Leukemia 44Sarcoma 43Prostatic Neoplasms 39Multiple Myeloma 36Head and Neck Neoplasms 36Central Nervous System Neoplasms 36Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 31Carcinoma, Ovarian Epithelial 30Melanoma 29Rectal Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lymphoma, Large B-Cell, Diffuse 26Brain Neoplasms 26Urinary Bladder Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Leukemia, Myeloid, Acute 23Fallopian Tube Neoplasms 23Endometrial Neoplasms 22Glioblastoma 21Adenocarcinoma of Lung 21Lymphoma, Mantle-Cell 18Gliosarcoma 17

Interventions

lorvotuzumab mertansine 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Pleuropulmonary blastoma × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡